Skip to main content
v2026.11,986 entries · CC-BY 4.0

Editorial · CASRAI · Compliance and regulatory

EMA seeks comments on revised medically important veterinary safety terms

EMA is consulting on a standalone list of medically important VeDDRA terms, with comments due by 31 January 2027.

Published 17 Nov 2026· 5 minute read

Ask CASRAI · free to try

Ask about this story

2 free questions a day, no account.

An AI assistant for research: funder rules, compliance, methods and publishing. It links the sources behind its answers and labels answers that come from a web search.

Answers draw on CASRAI's guides and dictionary plus the federal and funder documents we index: Federal Register, Grants.gov, Regulations.gov and UKRI.

Works on this site and inside Claude, Cursor and the AI tools you already use.

Everything CASRAI publishes — this page, the dictionary, the guides and the news — stays open to read, with no account and no card.

CASRAI is the reference for research administration — bookmark it for the next question.

The European Medicines Agency opened a public consultation on 13 November 2026 on a revised list of medically important veterinary safety-reporting terms, with comments due by 31 January 2027. The draft would separate the list from its signal-management guideline, making it relevant to research teams maintaining veterinary pharmacovigilance databases, terminology mappings and safety-study records.

EMA proposes a standalone medically important terms list

The 12-page draft, reference EMA/CVMP/PhVWP/220641/2026, would replace Appendix 1 of the veterinary good pharmacovigilance practices signal-management module. EMA explicitly says the separation is intended to make the list easier to update when needed. The proposal therefore concerns both the contents of the list and how that reference document is maintained.

EMA’s Committee for Veterinary Medicinal Products adopted the text for release for consultation on 5 November. Its November meeting highlights record that decision; the draft’s cover supplies the subsequent opening date and exact comment deadline. Release for consultation is the current development. The document remains a draft, with final adoption and coming-into-effect dates left unassigned.

The list uses VeDDRA preferred terms, abbreviated PTs, and identifies the species for which each entry is medically important. The introduction describes the list as a tool for prioritising signal detection and management. Inclusion can reflect medical importance independently of an established causal association with a veterinary medicinal product. A list entry consequently does not establish that a medicine caused a reported event.

For database and terminology teams, the structure matters: a preferred term and its species designation must be considered together when interpreting the proposed list. The draft’s table has three columns: preferred term, medically important status by species, and a change marker comparing the entry with the previous list. Those markers distinguish unchanged entries, new medically important terms and species, species changes, and deletions.

Examples from the consultation table show the kinds of changes available for scrutiny:

  • Abdominal pain: the species designation is equine, marked as a species change.
  • Environmental incident: the species field says not applicable, with the entry marked as new.
  • Convulsion: marked for deletion from this list because it is covered by the preferred term Seizure.
  • Aggression: marked for removal from this list because of insufficient specificity.

These are proposed changes to the medically important list. The table’s deletion marker should not be read as an announcement that a term has been deleted from the entire VeDDRA terminology. EMA also says the comparison column will be removed in the final version, giving consultation respondents a specific opportunity to examine the documented differences now.

A wider signal-management revision has its own timetable

EMA’s VGVP document register places the new list alongside a separate draft revision of the signal-management module. The existing module was first published in November 2021 and has a listed effective date of 28 January 2022. A concept paper consulted on earlier in 2026 described revising it using experience gained with the veterinary medicines framework.

The register describes the revised module as covering scientific and quality aspects of signal management, together with roles, responsibilities and procedures. It lists that consultation as running from 18 September to 18 December 2026. The standalone medically important terms consultation instead closes on 31 January 2027. Institutions contributing to both need to keep the two deadlines separate.

Independent coverage focuses on the consultation opportunity

In its 16 November regulatory brief, Gulfstream Intelligence founder Scott Morvay identified EMA’s veterinary consultations as formal opportunities to comment on pharmacovigilance terminology and analytical-method validation. The terminology proposal is distinct from the separate GL49 consultation on veterinary residue-study methods.

VigiEye’s 15 November analysis likewise highlighted the move from an appendix to a standalone guideline and its relationship with the signal-management module. EMA’s own register provides the separate closing dates. The immediate institutional opportunity is to review and comment on the proposed reference list.

What research teams can examine before 31 January

For universities and research organisations supporting veterinary pharmacovigilance work, the practical implication is a focused review of terminology dependencies. A research data dictionary can identify where preferred terms, species and medically important flags are stored. Comparing those fields with the draft’s change column can reveal whether a local mapping treats a species-specific entry as universal or retains an obsolete cross-reference.

This is an implication of the proposed structure, rather than a new implementation requirement for universities. Teams preparing comments can connect concrete mapping examples with the relevant draft entries. Research offices coordinating those responses can also identify standard operating procedures that cite the existing appendix and distinguish the document reference from the underlying database rule. Keeping that distinction explicit supports data integrity when explaining which list version informed a study record or analysis.

EMA requests comments through its linked template, with the completed form sent to [email protected]. The next dated milestone for this proposal is the close of comments on 31 January 2027. The consultation gives participating institutions a route to raise specific questions about the list’s terminology, species assignments and relationship with signal management before finalisation.

Sources

Referenced across the research world

University of Cambridge logoColumbia University logoCrossref logoUniversity of Edinburgh logoHarvard University logoUniversity of Oxford logoPrinceton University logoStanford School of Medicine logoUniversity College London logoORCID logoUniversity of Cambridge logoColumbia University logoCrossref logoUniversity of Edinburgh logoHarvard University logoUniversity of Oxford logoPrinceton University logoStanford School of Medicine logoUniversity College London logoORCID logo
  • University of Cambridge logo
  • Columbia University logo
  • Crossref logo
  • University of Edinburgh logo
  • Harvard University logo
  • University of Oxford logo
  • Princeton University logo
  • Stanford School of Medicine logo
  • University College London logo
  • ORCID logo

View CASRAI adoption →